507 related articles for article (PubMed ID: 31220725)
21. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
22. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Hosokawa M; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
[TBL] [Abstract][Full Text] [Related]
23. DNA methyltransferase- and histone deacetylase-mediated epigenetic alterations induced by low-level methylmercury exposure disrupt neuronal development.
Go S; Kurita H; Hatano M; Matsumoto K; Nogawa H; Fujimura M; Inden M; Hozumi I
Arch Toxicol; 2021 Apr; 95(4):1227-1239. PubMed ID: 33454822
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
26. HDAC as a therapeutic target for treatment of endometrial cancers.
Ren J; Zhang J; Cai H; Li Y; Zhang Y; Zhang X; Zhao D; Li Z; Ma H; Wang J; Gao YE; Xiao L; Liu R; Qian J; Liu Y; Wei H; Li J
Curr Pharm Des; 2014; 20(11):1847-56. PubMed ID: 23888962
[TBL] [Abstract][Full Text] [Related]
27. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
29. Potential epigenetic therapeutics for atherosclerosis treatment.
Nicorescu I; Dallinga GM; de Winther MPJ; Stroes ESG; Bahjat M
Atherosclerosis; 2019 Feb; 281():189-197. PubMed ID: 30340764
[TBL] [Abstract][Full Text] [Related]
30. Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.
Salarinia R; Sahebkar A; Peyvandi M; Mirzaei HR; Jaafari MR; Riahi MM; Ebrahimnejad H; Nahand JS; Hadjati J; Asrami MO; Fadaei S; Salehi R; Mirzaei H
Curr Cancer Drug Targets; 2016; 16(9):773-788. PubMed ID: 26638884
[TBL] [Abstract][Full Text] [Related]
31. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
33. Influence of epigenetic modifications of the interleukin-10 promoter on IL10 gene expression.
Larsson L; Thorbert-Mros S; Rymo L; Berglundh T
Eur J Oral Sci; 2012 Feb; 120(1):14-20. PubMed ID: 22288916
[TBL] [Abstract][Full Text] [Related]
34. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
37. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
38. Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications.
Inoue F; Sone K; Toyohara Y; Takahashi Y; Kukita A; Hara A; Taguchi A; Tanikawa M; Tsuruga T; Osuga Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669072
[TBL] [Abstract][Full Text] [Related]
39. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
Meng CF; Su B; Li W
Mol Med Rep; 2011; 4(6):1273-8. PubMed ID: 21850374
[TBL] [Abstract][Full Text] [Related]
40. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
